114 related articles for article (PubMed ID: 38679213)
21. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic efficacy induced by the oral administration of Agaricus blazei Murill against Leishmania amazonensis.
Valadares DG; Duarte MC; Ramírez L; Chávez-Fumagalli MA; Lage PS; Martins VT; Costa LE; Ribeiro TG; Régis WC; Soto M; Fernandes AP; Tavares CA; Coelho EA
Parasitol Res; 2012 Oct; 111(4):1807-16. PubMed ID: 22797606
[TBL] [Abstract][Full Text] [Related]
23. 2'-Hydroxyflavanone activity in vitro and in vivo against wild-type and antimony-resistant Leishmania amazonensis.
Gervazoni LFO; Gonçalves-Ozório G; Almeida-Amaral EE
PLoS Negl Trop Dis; 2018 Dec; 12(12):e0006930. PubMed ID: 30521527
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo activity of a palladacycle complex on Leishmania (Leishmania) amazonensis.
Paladi Cde S; Pimentel IA; Katz S; Cunha RL; Judice WA; Caires AC; Barbiéri CL
PLoS Negl Trop Dis; 2012; 6(5):e1626. PubMed ID: 22616018
[TBL] [Abstract][Full Text] [Related]
25. Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model.
Lecoeur H; Buffet P; Morizot G; Goyard S; Guigon G; Milon G; Lang T
PLoS Negl Trop Dis; 2007 Nov; 1(2):e34. PubMed ID: 18060082
[TBL] [Abstract][Full Text] [Related]
26. Antileishmanial activity of Urtica dioica extract against zoonotic cutaneous leishmaniasis.
Badirzadeh A; Heidari-Kharaji M; Fallah-Omrani V; Dabiri H; Araghi A; Salimi Chirani A
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007843. PubMed ID: 31929528
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis.
Mussi SV; Fernandes AP; Ferreira LA
Parasitol Res; 2007 May; 100(6):1221-6. PubMed ID: 17206508
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
[TBL] [Abstract][Full Text] [Related]
29. DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis.
Celes FS; Trovatti E; Khouri R; Van Weyenbergh J; Ribeiro SJ; Borges VM; Barud HS; de Oliveira CI
Sci Rep; 2016 Dec; 6():38330. PubMed ID: 27922065
[TBL] [Abstract][Full Text] [Related]
30. In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis.
Garnier T; Brown MB; Lawrence MJ; Croft SL
J Pharm Pharmacol; 2006 Aug; 58(8):1043-54. PubMed ID: 16872550
[TBL] [Abstract][Full Text] [Related]
31. Treatment with synthetic lipophilic tyrosyl ester controls Leishmania major infection by reducing parasite load in BALB/c mice.
Sghaier RM; Aissa I; Attia H; Bali A; Leon Martinez PA; Mkannez G; Guerfali FZ; Gargouri Y; Laouini D
Parasitology; 2016 Oct; 143(12):1615-21. PubMed ID: 27312247
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by Leishmania major.
Bemani E; Oryan A; Bahrami S
Exp Parasitol; 2019 Oct; 205():107747. PubMed ID: 31442454
[TBL] [Abstract][Full Text] [Related]
33. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.
Schmidt-Ott R; Klenner T; Overath P; Aebischer T
Trans R Soc Trop Med Hyg; 1999; 93(1):85-90. PubMed ID: 10492799
[TBL] [Abstract][Full Text] [Related]
34. High-through identification of T cell-specific phage-exposed mimotopes using PBMCs from tegumentary leishmaniasis patients and their use as vaccine candidates against Leishmania amazonensis infection.
Carvalho GB; Costa LE; Lage DP; Ramos FF; Santos TTO; Ribeiro PAF; Dias DS; Salles BCS; Lima MP; Carvalho LM; Dias ACS; Alves PT; Franklin ML; Silva RAM; Duarte MC; Menezes-Souza D; Roatt BM; Chávez-Fumagalli MA; Goulart LR; Teixeira AL; Coelho EAF
Parasitology; 2019 Mar; 146(3):322-332. PubMed ID: 30198459
[TBL] [Abstract][Full Text] [Related]
35. Topical tamoxifen in the therapy of cutaneous leishmaniasis.
Trinconi CT; Reimão JQ; Bonano VI; Espada CR; Miguel DC; Yokoyama-Yasunaka JKU; Uliana SRB
Parasitology; 2018 Apr; 145(4):490-496. PubMed ID: 28274283
[TBL] [Abstract][Full Text] [Related]
36. Combined therapy with adipose tissue-derived mesenchymal stromal cells and meglumine antimoniate controls lesion development and parasite load in murine cutaneous leishmaniasis caused by Leishmania amazonensis.
Ramos TD; Silva JD; da Fonseca-Martins AM; da Silveira Pratti JE; Firmino-Cruz L; Maciel-Oliveira D; Dos-Santos JS; Tenorio JIN; de Araujo AF; Freire-de-Lima CG; Diaz BL; Cruz FF; Rocco PRM; de Matos Guedes HL
Stem Cell Res Ther; 2020 Aug; 11(1):374. PubMed ID: 32867857
[TBL] [Abstract][Full Text] [Related]
37. Activity, toxicity and analysis of resistance of essential oil from Chenopodium ambrosioides after intraperitoneal, oral and intralesional administration in BALB/c mice infected with Leishmania amazonensis: a preliminary study.
Monzote L; Montalvo AM; Scull R; Miranda M; Abreu J
Biomed Pharmacother; 2007; 61(2-3):148-53. PubMed ID: 17254746
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility to paromomycin in clinical isolates and reference strains of Leishmania species responsible for tegumentary leishmaniasis in Brazil.
Coser EM; Ferreira BA; Yamashiro-Kanashiro EH; Lindoso JAL; Coelho AC
Acta Trop; 2021 Mar; 215():105806. PubMed ID: 33385363
[TBL] [Abstract][Full Text] [Related]
39. A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasis.
Sousa JKT; Antinarelli LMR; Mendonça DVC; Lage DP; Tavares GSV; Dias DS; Ribeiro PAF; Ludolf F; Coelho VTS; Oliveira-da-Silva JA; Perin L; Oliveira BA; Alvarenga DF; Chávez-Fumagalli MA; Brandão GC; Nobre V; Pereira GR; Coimbra ES; Coelho EAF
Parasitol Int; 2019 Dec; 73():101966. PubMed ID: 31362122
[TBL] [Abstract][Full Text] [Related]
40. 2,3,7,8-tetrachlorodibenzo-p-dioxin slows the progression of experimental cutaneous Leishmaniasis in susceptible BALB/c and SCID mice.
DeKrey GK; Teagarden RE; Lenberg JL; Titus RG
PLoS One; 2013; 8(10):e76259. PubMed ID: 24098456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
